Clover Biopharmaceuticals Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
257
- Stock Symbol
-
02197
- Share Price
-
$0.22
- (As of Thursday Closing)
Clover Biopharmaceuticals General Information
Description
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to unleashing the power of vaccines to save lives and improve health around the world. The leverage the proprietary Trimer-Tag technology platform to conduct R&D for vaccines that can fulfill unmet needs, with a focus on building a respiratory vaccine franchise to reduce the burden of vaccine-preventable diseases. The Group has only one operating segment, which is the research and development, manufacturing, and commercialisation of vaccines. Geographically, the company earns revenue from Mainland China and Korea.
Contact Information
Website
www.cloverbiopharma.comCorporate Office
- 49F, Transocean Plaza, Nanjing West Road
- Jing'an District
- Shanghai, 200040
- China
Corporate Office
- 49F, Transocean Plaza, Nanjing West Road
- Jing'an District
- Shanghai, 200040
- China
Clover Biopharmaceuticals Stock Performance
As of 12-Nov-2026, Clover Biopharmaceuticals’s stock price is $0.22. Its current market cap is $283M with 1.3B shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.22 | $0.21 | $0.14 - $0.41 | $283M | 1.3B | 3.28M | $0.10 |
Clover Biopharmaceuticals Financials Summary
As of 30-Jun-2026, Clover Biopharmaceuticals has a trailing 12-month revenue of $61.5K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 229,080 | 334,862 | 3,463 | (13,859) |
| Revenue | 61 | 487 | 5,354 | 5,549 |
| EBITDA | 124,718 | (25,562) | (122,784) | (9,231) |
| Net Income | 121,639 | (28,519) | (125,905) | (19,582) |
| Total Assets | 35,594 | 65,448 | 111,333 | 296,453 |
| Total Debt | 307 | 1,517 | 12,280 | 47,182 |
Clover Biopharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Clover Biopharmaceuticals Comparisons
Industry
Financing
Details
Clover Biopharmaceuticals Competitors (9)
One of Clover Biopharmaceuticals’s 9 competitors is Asymchem, a Formerly VC-backed company based in Tianjin, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Asymchem | Formerly VC-backed | Tianjin, China | ||||
| HUTCHMED | Corporation | Hong Kong, Hong Kong | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| ACROBiosystems | Formerly VC-backed | Beijing, China | ||||
| MindWalk | Corporation | Austin, TX |
Clover Biopharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Clover Biopharmaceuticals Patents
Clover Biopharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026223323-A1 | Combo vaccines for respiratory diseases | Pending | 20-Apr-2025 | ||
| WO-2026092136-A1 | Combo vaccines for respiratory diseases | Pending | 28-Oct-2024 | ||
| AU-2025209513-A1 | Herpes simplex virus recombinant antigen and uses thereof | Pending | 19-Jan-2024 | ||
| WO-2025153100-A1 | Herpes simplex virus recombinant antigen and uses thereof | Pending | 19-Jan-2024 | ||
| AU-2024381754-A1 | Rsv vaccine composition, method, and use thereof | Pending | 13-Nov-2023 | C07K14/005 |
Clover Biopharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Clover Biopharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Clover Biopharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Clover Biopharmaceuticals FAQs
-
When was Clover Biopharmaceuticals founded?
Clover Biopharmaceuticals was founded in 2007.
-
Where is Clover Biopharmaceuticals headquartered?
Clover Biopharmaceuticals is headquartered in Shanghai, China.
-
What is the size of Clover Biopharmaceuticals?
Clover Biopharmaceuticals has 257 total employees.
-
What industry is Clover Biopharmaceuticals in?
Clover Biopharmaceuticals’s primary industry is Drug Discovery.
-
Is Clover Biopharmaceuticals a private or public company?
Clover Biopharmaceuticals is a Public company.
-
What is Clover Biopharmaceuticals’s stock symbol?
The ticker symbol for Clover Biopharmaceuticals is 02197.
-
What is the current stock price of Clover Biopharmaceuticals?
As of 12-Nov-2026 the stock price of Clover Biopharmaceuticals is $0.22.
-
What is the current market cap of Clover Biopharmaceuticals?
The current market capitalization of Clover Biopharmaceuticals is $283M.
-
What is Clover Biopharmaceuticals’s current revenue?
The trailing twelve month revenue for Clover Biopharmaceuticals is $61.5K.
-
Who are Clover Biopharmaceuticals’s competitors?
Asymchem, HUTCHMED, BeOne Medicines, ACROBiosystems, and MindWalk are some of the 9 competitors of Clover Biopharmaceuticals.
-
What is Clover Biopharmaceuticals’s annual earnings per share (EPS)?
Clover Biopharmaceuticals’s EPS for 12 months was $0.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
